Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.49 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.48 |
| ▸ | KDR | P35968 | 9/20 | 0.46 |
| ▸ | BRAF | P15056 | 4/20 | 0.46 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.44 |
| ▸ | ULK1 | O75385 | 1/20 | 0.43 |
| ▸ | UBE2M | P61081 | 1/20 | 0.42 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.42 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.42 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.41 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.41 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13256817 | 0.92 | ULK1 (0.53) | ARGRM4KDRBRAFPSMB8 | |
| SCHEMBL9892891 | 0.89 | EPHX2 (0.52) | KDRPSMB8ULK1 | |
| SCHEMBL22644328 | 0.84 | AR (0.47) | ARGRM4KDRBRAFUBE2M | |
| SCHEMBL13256812 | 0.82 | ULK1 (0.53) | KDRPSMB8ULK1 | |
| SCHEMBL29640005 | 0.80 | KDR (0.57) | GRM4KDRPSMB8ULK1 | |
| SCHEMBL31421815 | 0.79 | ULK1 (0.52) | PSMB8ULK1 | |
| SCHEMBL26696301 | 0.78 | AR (0.46) | ARGRM4KDRBRAFUBE2M | |
| SCHEMBL5383096 | 0.78 | AR (0.46) | ARGRM4KDRBRAFUBE2M | |
| SCHEMBL29640015 | 0.78 | PSMB8 (0.57) | KDRPSMB8ULK1 | |
| SCHEMBL31122474 | 0.78 | PSMB8 (0.57) | KDRPSMB8ULK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2443107-B1 | AZETIDINE 2 -CARBOXAMIDE DERIVATIVES WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INT (DE) | 2018-08-08 | — | — | EP | disclosed |
| US-8383615-B2 | Azetidine 2-carboxamide derivatives which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-02-26 | — | — | US | disclosed |
| US-20120142666-A1 | Azetidine 2-Carboxamide Derivatives Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
| WO-2010147791-A1 | AZETIDINE 2 -CARBOXAMIDE DERIVATIVES WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142666-A1 | Azetidine 2-Carboxamide Derivatives Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | AR 631/4885GRM4 529/4885KDR 952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.